Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Severe asthma Type 2-low is a phenotype of severe asthma characterized by limited Type 2 inflammatory biomarkers. According to Porpodis et al. (2025), T2-low asthma accounted for 20.1% of 602 adults with severe asthma enrolled across the PHOLLOW study. The findings indicate a substantial burden of uncontrolled asthma among affected patients. According to the severe asthma type 2-low epidemiology forecast by Expert Market Research, the condition is expected to remain an important severe-asthma phenotype.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Severe Asthma Type 2-Low – Number of Cases by Year

Read more about this report - Request a Free Sample

Severe Asthma Type 2-Low Epidemiology Forecast Report Coverage

Expert Market Research's “Severe Asthma Type 2-Low Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of severe asthma type 2-low. It projects the future incidence and prevalence rates of severe asthma type 2-low cases across various populations. The study covers age, gender, and type as major determinants of the severe asthma type 2-low population. The report highlights patterns in the prevalence of severe asthma type 2-low over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of severe asthma type 2-low in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Severe Asthma Type 2-Low Understanding: Disease Overview

Severe asthma type 2-low is a difficult-to-treat form of asthma in which airway inflammation occurs without the prominent eosinophilic, allergic, or interleukin-driven signature of type 2 disease. It is not transmitted between people and has no single causative organism; it arises from chronic airway inflammation shaped by environmental exposures such as smoking and ozone, as well as comorbid obesity. Recognized subtypes include neutrophilic and paucigranulocytic asthma, and low-inflammatory forms, which are often associated with corticosteroid insensitivity and persistent symptoms. Because biomarker cutoffs vary, identifying T2-low endotype patients remains challenging in routine clinical practice.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

India

High-Risk Population

Smokers, individuals with obesity, and older adults

Key Diagnostic Method

Spirometry

Major Risk Factor

Tobacco smoke exposure

Major gap in the market

Underdiagnosis and limited phenotyping of type 2-low severe asthma

Severe Asthma Type 2-Low Epidemiology Perspective

The severe asthma type 2-low epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the severe asthma type 2-low epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for severe asthma type 2-low and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

Type 2-low asthma represented 20.1% of 602 adults with severe asthma in the PHOLLOW study. Among patients with severe uncontrolled asthma, prevalence ranged from 18% to 39% based on different biomarker thresholds, as reported by Konstantinos Porpodis et al., 2025, and Arja Viinanen et al., 2023.

Gender-Specific Cases of the Disease

As per Yueh-Ying Han et al., 2025, type 2-low asthma in children was associated with a higher likelihood of being female compared with controls. Gender-related differences may contribute to variation in the epidemiological distribution of Type 2-low asthma across patient populations.

Age-Specific Cases of the Disease

According to Yueh-Ying Han et al., 2025, 231 of 505 children (45.7%) with asthma had Type 2-low asthma. The type 2-low group was also more likely to be older than controls, indicating variation in phenotype distribution across age groups.

Ethnicity-Wise Cases of the Disease

Ethnic and demographic characteristics can contribute to variation in asthma phenotype distribution through differences in environmental exposures, socioeconomic conditions, and underlying population characteristics. Yueh-Ying Han et al., 2025, reported racial and ethnic differences across asthma subtypes in children.

Mortality and Survival Analysis of the Disease

The epidemiological burden of type 2-low severe asthma is reflected by disease control and exacerbation patterns. According to Konstantinos Porpodis et al., 2025, 71.1% of type 2-low patients experienced at least one clinically significant exacerbation during the preceding year.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Neutrophilic Type 2-Low Asthma

Accounts for a major share of the recognized type 2-low inflammatory phenotypes and is characterized by neutrophilic airway inflammation. Smoking, air pollution, infections, obesity, and other environmental exposures can contribute to its development and persistence.

Paucigranulocytic Type 2-Low Asthma

Represents another major subtype of type 2-low asthma and is characterized by limited eosinophilic and neutrophilic airway inflammation. Airway hyperresponsiveness, structural airway changes, and non-inflammatory mechanisms may contribute to disease persistence.

Obesity-Related Type 2-Low Asthma

Represents an important clinical subtype, particularly among patients with excess body weight and metabolic dysfunction.

Others

Other type 2-low presentations include late-onset, aging-related, exposure-related, infection-associated, and airway-remodeling phenotypes, which contribute to the heterogeneity of the disease.

Severe Asthma Type 2-Low – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Severe Asthma Type 2-Low Epidemiology

The severe asthma type 2-low epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

Obesity-related Type 2-low asthma is an important clinical pattern in the pediatric population. According to Yueh-Ying Han et al., 2025, children with type 2-low asthma were more likely to be older, female, and overweight or obese. Current second-hand smoke exposure was also associated with Type 2-low asthma, supporting the relevance of metabolic and environmental factors in its epidemiological distribution.

Germany

Type 2-low severe asthma can be differentiated through low type 2 inflammatory biomarker profiles, particularly low blood eosinophil counts and fractional exhaled nitric oxide. Factors affecting identification include biomarker variability, corticosteroid exposure, and differences in the thresholds used to classify type 2-low asthma.

France

The epidemiological identification of type 2-low severe asthma in France is influenced by biomarker-defined phenotyping, particularly blood eosinophil and fractional exhaled nitric oxide levels. Variation in biomarker thresholds and repeated measurements can affect the identification and reported distribution of type 2-low asthma.

Italy

Type 2-low severe asthma in Italy is characterized epidemiologically through low type 2 inflammatory biomarker profiles. Its identification can be influenced by variation in blood eosinophil and fractional exhaled nitric oxide measurements and by the classification thresholds applied when distinguishing type 2-low from other severe asthma phenotypes.

Spain

Low-biomarker Type 2-low asthma in Spain is relevant to severe asthma phenotyping. Factors influencing its identification include blood eosinophil and fractional exhaled nitric oxide measurements, biomarker stability over time, and exposure to corticosteroid treatment, which may influence observed inflammatory biomarker levels.

United Kingdom

Non-eosinophilic/low-blood-eosinophil type 2-low asthma represents an important phenotype among patients with uncontrolled severe asthma. According to Bo Ding et al., 2024, 72.9% of patients with uncontrolled severe asthma had low blood eosinophil levels. The analysis also highlighted variability in eosinophil levels and possible suppression associated with corticosteroid exposure.

Japan

The available evidence supports assessment of type 2-low asthma within the broader severe asthma population through biomarker-based phenotyping. According to Toshiyuki Koya et al., 2023, severe asthma accounts for 2.4%–12.7% of asthma cases in Japan, providing an established population in which different severe asthma phenotypes can be evaluated.

India

Type 2-low severe asthma is an established phenotype within India's heterogeneous severe asthma population. According to Deepak Talwar et al., 2022, 15% of 100 adults with severe asthma had the type 2-low phenotype, characterized by low absolute eosinophil count and immunoglobulin E levels and absence of allergic symptoms.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

A major gap in severe asthma type 2-low disease management is the limited availability of validated biomarkers and standardized approaches for identifying non-type 2 inflammatory phenotypes. This can contribute to delayed phenotyping and treatment optimization, particularly in patients who remain uncontrolled despite conventional inhaled therapies. An important opportunity exists for improved diagnostic approaches incorporating inflammatory profiling, lung-function assessment, and clinical characteristics. Across the United States, Europe, Japan, and India, growing recognition of severe asthma heterogeneity may support demand for more personalized management strategies and the development of therapies targeting non-type 2 inflammatory pathways.

Severe Asthma Type 2-Low: Treatment Overview

Severe asthma type 2-low treatment focuses on achieving symptom control, reducing exacerbations, and improving lung function through optimized inhaled therapy and management of contributing factors. High-dose inhaled corticosteroids combined with long-acting beta2-agonists remain a foundation of treatment, although corticosteroid responsiveness may be limited in some type 2-low patients. Additional options include long-acting muscarinic antagonists, leukotriene receptor antagonists, and, when clinically appropriate, maintenance oral corticosteroids. Bronchodilator therapy and non-pharmacological measures, including smoking cessation, weight management, vaccination, and management of comorbidities, may support disease control.

Key Questions Answered

  • What is the current and projected burden of severe asthma type 2-low across the 8 major markets?
  • Which countries across the 8 major markets account for the highest severe asthma type 2-low patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of severe asthma type 2-low across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of severe asthma type 2-low across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of severe asthma type 2-low across the 8 major markets?
  • How do major comorbidities and risk factors influence severe asthma type 2-low epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of severe asthma type 2-low across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Severe Asthma Type 2-Low landscape across the 8 major markets?
  • Which therapeutic areas linked to severe asthma type 2-low are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the severe asthma type 2-low epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on severe asthma type 2-low epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for severe asthma type 2-low across the 8 major markets?

Scope of the Severe Asthma Type 2-Low Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of severe asthma type 2-low based on several factors.
  • Severe Asthma Type 2-Low Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The severe asthma type 2-low report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Asthma Treatment Market

Asthma Epidemiology Forecast

Asthma Pipeline Analysis

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us